Tmunity Raises $100m Series A To Fund Next-Gen T-Cell Therapy Trials
Tmunity launched in early 2016 with $10m in seed funding for novel T-cell therapies, two of which are now in the clinic. The company reunites former Novartis cell therapy head Oz Azam and CAR-T researchers from the University of Pennsylvania.
You may also be interested in...
Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.
A group is coordinating the development of standards for cell and gene therapies in a congressionally mandated effort that could help manufacturers produce these therapies at commercial scale.
Gilead's Kite acquisition may finally have appeased investors' thirst for a major deal with a transaction that will diversify revenue and expand its oncology portfolio.